Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Late Stage Chronic Kidney Disease Drugs Global Market Report 2025
Request Sample Buy Now
Global Late Stage Chronic Kidney Disease Drugs Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Late Stage Chronic Kidney Disease Drugs Global Market Report 2025

By Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders), By Indication Type (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Late Stage Chronic Kidney Disease Drugs Market Overview

• Late Stage Chronic Kidney Disease Drugs market size has reached to $7.08 billion in 2024

• Expected to grow to $12.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%

• Growth Driver: Surging Prevalence Of Chronic Kidney Diseases Sparks Growth In The Late-Stage CKD Drug Market

• Market Trend: Product Innovation In Late-Stage Chronic Kidney Disease Drug Market

• North America was the largest region in 2024.

What Is Covered Under Late Stage Chronic Kidney Disease Drugs Market?

Late-stage chronic kidney disease drugs refer to medicines that treat end-stage chronic kidney disease. It improves a patient's quality of life by halting the disease's course and avoiding or postponing the need for dialysis or a transplant.

The main late-stage chronic kidney disease drugs product types are calcimimetics, vitamin d, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics refer to a class of medications that increase signaling and lower parathyroid hormone (PTH) by activating the calcium-sensing receptor allosterically. The indication types are late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia channeled through hospital pharmacies, online pharmacies, and retail pharmacies.

Late Stage Chronic Kidney Disease Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Late Stage Chronic Kidney Disease Drugs Market Size 2025 And Growth Rate?

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $7.08 billion in 2024 to $7.86 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development

What Is The Late Stage Chronic Kidney Disease Drugs Market Growth Forecast?

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $12.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for CKD management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics.

The forecast of 11.4% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. nephrology centers by increasing costs of erythropoiesis-stimulating agents and phosphate binders imported from the UK and Ireland, potentially reducing dialysis outcomes and raising renal care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Late Stage Chronic Kidney Disease Drugs Market Segmented?

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders

2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

What Is Driving The Late Stage Chronic Kidney Disease Drugs Market? Surging Prevalence Of Chronic Kidney Diseases Sparks Growth In The Late-Stage CKD Drug Market

The high prevalence of chronic kidney diseases is expected to propel the growth of the late-stage chronic kidney disease drug market going forward. Chronic kidney diseases refer to a diverse range of conditions that affect the structure and operation of the kidneys. Late-stage chronic kidney disease drugs for chronic kidney disease are used to control blood pressure in patients and decrease protein loss to halt the progression of kidney impairment, manage symptoms, and avoid consequences. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, an estimated 14% of U.S. adults, or around 35.5 million people, are believed to be living with chronic kidney diseases. Therefore, the prevalence of chronic kidney disease is driving the growth of the late-stage chronic kidney disease drug market.

What Is Driving The Late Stage Chronic Kidney Disease Drugs Market? Rising Diabetes Prevalence Fuels Growth In Late-Stage Chronic Kidney Disease Drug Market

The high prevalence of diabetes is expected to propel the growth of the late-stage chronic kidney disease drug market going forward. Diabetes is a chronic disease characterized by elevated levels of blood glucose, which can lead to serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes is a well-established risk factor for the development of chronic kidney disease. Individuals with diabetes, especially if poorly managed, are at an increased risk of developing late-stage CKD. As the prevalence of diabetes rises globally, the incidence of CKD, particularly in its later stages, is expected to increase proportionally. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the high prevalence of diabetes is driving the growth of the late-stage chronic kidney disease drug market.

Who Are The Major Players In The Global Late Stage Chronic Kidney Disease Drugs Market?

Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc

What Are The Key Trends Of The Global Late Stage Chronic Kidney Disease Drugs Market? Product Innovation In Late-Stage Chronic Kidney Disease Drug Market

Product innovation is a key trend gaining popularity in the late-stage chronic kidney disease drug market. Major companies operating in the late-stage chronic kidney disease drug market are developing new product drugs to sustain their position in the market. For instance, in February 2022, Bayer, a Germany-based pharmaceutical and biotechnology company, launched Kerendia (finerenone) in India. Patients with type two diabetes and chronic renal disease should use finer enone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist. It works by preventing the overactivation of the mineralocorticoid receptor (MR), which is thought to be a factor in developing chronic kidney disease (CKD) and cardiovascular harm.

What Are The Key Trends Of The Global Late Stage Chronic Kidney Disease Drugs Market? Advancements in Continuous Infusion Technologies for Kidney Disease Management

Major companies operating in the late-stage chronic kidney disease drugs market are developing technologies such as continuous subcutaneous infusion approaches to enhance treatment efficacy, improve patient outcomes, and streamline the drug development process. Continuous subcutaneous infusion technology delivers medication steadily through a small device placed under the skin, providing consistent therapeutic levels and improving patient adherence. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA (for levodopa/foscarbidopa). PRODUODOPA allows for a continuous infusion of levodopa, which helps maintain consistent dopamine levels in the bloodstream. This is crucial for managing symptoms effectively, as it extends the duration of "on" time—periods when symptoms are well-controlled—while minimizing "off" time when symptoms return.

Need data on a specific region in this market?
Request Customisation

Late Stage Chronic Kidney Disease Drugs Market Merger And Acquisition: AstraZeneca Expands Cardiorenal Pipeline Acquisition Of CinCor Pharma Inc And Baxdrostat

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. The addition of CinCor's potential medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) to treat chronic kidney disorders, will strengthen AstraZeneca's cardiorenal pipeline. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company and developer of baxdrostat.

Regional Outlook For The Global Late Stage Chronic Kidney Disease Drugs Market

North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Late Stage Chronic Kidney Disease Drugs Market?

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Late Stage Chronic Kidney Disease Drugs Industry?

The late stage chronic kidney disease drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Late Stage Chronic Kidney Disease Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $7.86 billion
Revenue Forecast In 2034 $12.11 billion
Growth Rate CAGR of 11.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies Subsegments: 1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Late Stage Chronic Kidney Disease Drugs Market Characteristics

3. Late Stage Chronic Kidney Disease Drugs Market Trends And Strategies

4. Late Stage Chronic Kidney Disease Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Late Stage Chronic Kidney Disease Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Late Stage Chronic Kidney Disease Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Late Stage Chronic Kidney Disease Drugs Market Growth Rate Analysis

5.4. Global Late Stage Chronic Kidney Disease Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Late Stage Chronic Kidney Disease Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Late Stage Chronic Kidney Disease Drugs Total Addressable Market (TAM)

6. Late Stage Chronic Kidney Disease Drugs Market Segmentation

6.1. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Calcimimetics

Vitamin D

Sterols

Potassium Binders

Calcium-Based Phosphate Binders

6.2. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Late Stage Chronic Kidney Disease Induced Hyperparathyroidism

Late Stage Chronic Kidney Disease Induced Hyperphosphatemia

Late Stage Chronic Kidney Disease Induced Hyperkalemia

6.3. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

6.4. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cinacalcet

Etelcalcetide

6.5. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Calcitriol

Doxercalciferol

Paricalcitol

6.6. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ergocalciferol

Cholecalciferol

6.7. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sodium Polystyrene Sulfonate

Patiromer

Sodium Zirconium Cyclosilicate

6.8. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Calcium Acetate

Calcium Carbonate

7. Late Stage Chronic Kidney Disease Drugs Market Regional And Country Analysis

7.1. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market

8.1. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Late Stage Chronic Kidney Disease Drugs Market

9.1. China Late Stage Chronic Kidney Disease Drugs Market Overview

9.2. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Late Stage Chronic Kidney Disease Drugs Market

10.1. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Late Stage Chronic Kidney Disease Drugs Market

11.1. Japan Late Stage Chronic Kidney Disease Drugs Market Overview

11.2. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Late Stage Chronic Kidney Disease Drugs Market

12.1. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Late Stage Chronic Kidney Disease Drugs Market

13.1. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Late Stage Chronic Kidney Disease Drugs Market

14.1. South Korea Late Stage Chronic Kidney Disease Drugs Market Overview

14.2. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Late Stage Chronic Kidney Disease Drugs Market

15.1. Western Europe Late Stage Chronic Kidney Disease Drugs Market Overview

15.2. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Late Stage Chronic Kidney Disease Drugs Market

16.1. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Late Stage Chronic Kidney Disease Drugs Market

17.1. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Late Stage Chronic Kidney Disease Drugs Market

18.1. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Late Stage Chronic Kidney Disease Drugs Market

19.1. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Late Stage Chronic Kidney Disease Drugs Market

20.1. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market

21.1. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market Overview

21.2. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Late Stage Chronic Kidney Disease Drugs Market

22.1. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Late Stage Chronic Kidney Disease Drugs Market

23.1. North America Late Stage Chronic Kidney Disease Drugs Market Overview

23.2. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Late Stage Chronic Kidney Disease Drugs Market

24.1. USA Late Stage Chronic Kidney Disease Drugs Market Overview

24.2. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Late Stage Chronic Kidney Disease Drugs Market

25.1. Canada Late Stage Chronic Kidney Disease Drugs Market Overview

25.2. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Late Stage Chronic Kidney Disease Drugs Market

26.1. South America Late Stage Chronic Kidney Disease Drugs Market Overview

26.2. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Late Stage Chronic Kidney Disease Drugs Market

27.1. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Late Stage Chronic Kidney Disease Drugs Market

28.1. Middle East Late Stage Chronic Kidney Disease Drugs Market Overview

28.2. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Late Stage Chronic Kidney Disease Drugs Market

29.1. Africa Late Stage Chronic Kidney Disease Drugs Market Overview

29.2. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape And Company Profiles

30.1. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape

30.2. Late Stage Chronic Kidney Disease Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Late Stage Chronic Kidney Disease Drugs Market Other Major And Innovative Companies

31.1. Sanofi SA

31.2. Bristol-Myers Squibb Company

31.3. AstraZeneca plc

31.4. Eli Lilly and Company

31.5. C.H. Boehringer Sohn AG & Co. KG

31.6. Amgen Inc.

31.7. Novo Nordisk A/S

31.8. Teva Pharmaceutical Industries Ltd.

31.9. Otsuka Pharmaceutical Co. Ltd.

31.10. Takeda Pharmaceutical Company Limited

31.11. Kyowa Kirin Co Ltd.

31.12. OPKO Health Inc.

31.13. Evotec SE

31.14. Ionis Pharmaceuticals Inc.

31.15. Akebia Therapeutics Inc.

32. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Late Stage Chronic Kidney Disease Drugs Market

34. Recent Developments In The Late Stage Chronic Kidney Disease Drugs Market

35. Late Stage Chronic Kidney Disease Drugs Market High Potential Countries, Segments and Strategies

35.1 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Late Stage Chronic Kidney Disease Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Late Stage Chronic Kidney Disease Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Johnson & Johnson Financial Performance
  • Table 81: AbbVie Inc. Financial Performance
  • Table 82: Bayer AG Financial Performance
  • Table 83: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Late Stage Chronic Kidney Disease Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Late Stage Chronic Kidney Disease Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Johnson & Johnson Financial Performance
  • Figure 81: AbbVie Inc. Financial Performance
  • Figure 82: Bayer AG Financial Performance
  • Figure 83: Novartis AG Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Fiberglass Roving Global Market Report 2025 – By Product Type (Single-End Roving, Multi-End Roving, Chopped Roving), By Fiberglass Type (E-glass, ECR-glass, H-glass, AR-glass, S-glass), By Application (Electrical And Ele...

View Report

Kidney Cancer Drugs Global Market Report 2025 – By Type (Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)), By Product (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (E...

View Report

8K Technology Global Market Report 2025 – By Product (8K Television, 8K Camera, 8K Monitors Or Laptops, 8K Projectors, Other Products), By Resolution (7680 x 4320, 8192 x 8192, 8192 x 5120, 8192 x 4320), By End-User (Con...

View Report

Smart City Platforms Global Market Report 2025 – By Offering (Platforms, Services), By Deployment Model (On Premise, Cloud), By Delivery Model (Offshore, Hybrid, Onshore), By Application (Smart Infrastructure, Smart Gove...

View Report

Commercial Buildings Global Market Report 2025 – By Product (New Construction, Repair And Maintenance, Refurbishment And Demolition), By Application (Owned, Rental), By End User (Offices, Retail, Leisure, Other End Users...

View Report

Robot Assisted Endoscope Global Market Report 2025 – By Product (Diagnostic, Therapeutic), By Application (Laparoscopy, Bronchoscopy, Colonoscopy), By End- User (Hospitals, Ambulatory Surgical Centers, Other End-User) – ...

View Report

Corporate Training Global Market Report 2025 – By Training Programs (Technical Training, Soft Skills Training, Quality Training, Compliance Training, Other Training Programs), By Training Methods (Virtual, Face-To-Face),...

View Report

Dry Eye Products Global Market Report 2025 – By Product (Antibiotic Drops, Hormone Drops, Artificial Tears, Other Products), By Type (Prescription Drugs, Over-The-Counter Drugs), By Distribution Channel (Hospital Pharmac...

View Report

Frequently Asked Questions

Late-stage chronic kidney disease drugs refer to medicines that treat end-stage chronic kidney disease. It improves a patient's quality of life by halting the disease's course and avoiding or postponing the need for dialysis or a transplant. For further insights on this market, request a sample here

The market major growth driver - Surging Prevalence Of Chronic Kidney Diseases Sparks Growth In The Late-Stage CKD Drug Market. For further insights on this market, request a sample here

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $7.08 billion in 2024 to $7.86 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to " $12.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for CKD management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics. For further insights on this market, request a sample here

The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate For further insights on this market, request a sample here

North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc . For further insights on this market, request a sample here.

Major trends in this market include Product Innovation In Late-Stage Chronic Kidney Disease Drug Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Late Stage Chronic Kidney Disease Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon